Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged &#8805;65 Years.

Yoo, Byung Wook; Kim, Chang Oh; Izu, Allen; Arora, Ashwani Kumar; Heijnen, Esther

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years.

Yoo, Byung Wook; Kim, Chang Oh; Izu, Allen; Arora, Ashwani Kumar; Heijnen, Esther.

Afiliação

Yoo BW; Department of Family Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Kim CO; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Izu A; Novartis Vaccines, Seqirus USA Inc., Cambridge, MA, USA.
Arora AK; Novartis Vaccines, Seqirus S.r.l. Siena, Italy.
Heijnen E; Novartis Vaccines, Seqirus Netherlands, Amsterdam, The Netherlands. estherheijnen@gmail.com.

Infect Chemother ; 50(4): 301-310, 2018 Dec.

Article em En | MEDLINE | ID: mdl-30600653

Palavras-chave

Adjuvant; Influenza; MF59; Older adults; Trivalent influenza vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Screening_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google